Evidence
Zhonghua Gan Zang Bing Za Zhi. 2023 Aug 20;31(8):793-797. doi: 10.3760/cma.j.cn501113-20230801-00026.
ABSTRACT
Fatty liver disease has undergone a major name change, with metabolic dysfunction-associated fatty liver disease (MASLD) replacing nonalcoholic fatty liver disease. The definition of MASLD no longer requires the exclusion of other co-existing liver diseases but instead associates hepatic steatosis with overweight/obesity, type 2 diabetes mellitus, or metabolic disorders and clearly defines the amount of alcohol consumption. The new definition also introduces the concepts of metabolic-related alcoholic liver disease and cryptogenic fatty liver disease. These changes will bring new challenges and opportunities for the design of clinical trials of fatty liver disease drugs and the selection of target populations.
PMID:37723059 | DOI:10.3760/cma.j.cn501113-20230801-00026
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 2 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Fatty liver disease’s renaming impacts on drug clinical trials
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
Fatty liver disease’s renaming impacts on drug clinical trials
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Fatty liver disease’s renaming impacts on drug clinical trials
🌐 365 Days
VR Related Evidence Matrix
